Abstract: A VOC free cross linking product for waterborn coatings is described. The crosslinking product comprises at least one cross linking agent and at least one viscosity reducing compound.

Abstract: The present invention relates to a hydroxy-sulphureous acid, to a method for preparation of the hydroxysulphureous acid and to products based on said hydroxysulphureous acid, to methods for preparation of said products and to use of said products, wherein said hydroxysulphureous acid is used as building blocks for polymer systems, e g aqueous polymer systems such as inks, coatings, and adhesives.

Abstract: A method for coating a floor, wherein said method comprises applying an aqueous dispersion comprising polyurethane, an acrylate or a hybride or mixture thereof; drying said coating and subjecting the physically dry coating to ultraviolet radiation whereby a cured coating is obtained. Also claimed is reactive additives suitable for use in the methods as well as the floor itself.

Abstract: The present invention relates to a hydroxy-sulphureous acid, to a method for preparation of the hydroxysulphureous acid and to products based on said hydroxysulphureous acid, to methods for preparation of said products and to use of said products, wherein said hydroxysulphureous acid is used as building blocks for polymer systems, e g aqueous polymer systems such as inks, coatings, and adhesives.

Abstract: A process for manufacture of a dendritic polyether comprising a core, derived from a compound having two or more hydroxyl groups, and at least one branching generation being built up from at least one hydroxyoxetane having one oxetane group and at least one hydroxyl group is disclosed. The process comprises ring opening addition to said core and ring opening polymerization of said hydroxyoxetane. A mixture of the core compound and at least one cationic initiator is prepared and said hydroxyoxetane is fed to said mixture at a rate resulting in and/or maintaining a reaction temperature below onset at thermal degradation and in an amount resulting in at least one branching generation. The initiator is present in an amount of 0.1–0.5% by weight calculated on said core and said oxetane, preferably in an amount giving a ratio hydroxyl groups to initiator of between 1:0.01 and 1:0.05. Yielded dendritic polyether is sebsequently neutralised by addition of at least one alkaline compound and optionally purified.

Abstract: A process for manufacture of a dendritic polyether comprising a core, derived from a compound having two or more hydroxyl groups, and at least one branching generation being built up from at least one hydroxyoxetane having one oxetane group and at least one hydroxyl group is disclosed. The process comprises ring opening addition to said core and ring opening polymerisation of said hydroxyoxetane. A mixture of the core compound and at least one cationic initiator is prepared and said hydroxyoxetane is fed to said mixture at a rate resulting in and/or maintaining a reaction temperature below onset at thermal degradation and in an amount resulting in at least one branching generation. The initiator is present in an amount of 0.1-0.5% by weight calculated on said core and said oxetane, preferably in an amount giving a ratio hydroxyl groups to initiator of between 1:0.01 and 1:0.05. Yielded dendritic polyether is sebsequently neutralised by addition of at least one alkaline compound and optionally purified.

Abstract: A hyperbranched dendritic polyether, which optionally is further processed, such as further chain extended, chain terminated and/or functionalised. The hyperbranched dendritic polyether is obtained in a process comprising the step of thermally initiated cationic ring-opening polymerisation of at least one oxetane having at least two reactive groups of which at least one is an oxetane group. The thermally initiated ring-opening polymerisation is performed using an effective amount of at least one initiator, such as a thermal onium salt, a Lewis acid and/or a Brønsted acid. The terminal groups in said hyperbranched dendritic polyether are substantially hydroxyl groups and used for said optional further processing.

Abstract: A process for production of an oxetane, which process comprises subjecting an alcohol having two or more hydroxyl groups to reaction with a carbamide at a molar ratio employing 1-2 moles of said carbamide on 1-2 moles of said alcohol. The alcohols preferably have at least one 1,3-diol grouping. The reaction is carried out in the presence of at least one catalyst promoting and/or initiating transcarbonylation and/or pyrolysis. A reaction mixture comprising an oxetane and optionally an orthocarbonate of said alcohol is yielded. The oxetane is suitable recovered from said reaction mixture by for instance distillation.

Abstract: The present invention relates to derivatives of phosphorylated carbohydrates and pharmaceutical compositions comprising as a pharmaceutically active ingredient at least one of these compounds.

Abstract: A process for synthesis of a polymeric polyalcohol substantially and preferably built up form polyester units and composed of a monomeric or polymeric initiator molecule to which at least one dentritic branch (dendron) consisting of a number of branching generations is added. The branching generations comprise a polymericor monomeric branching chain extender having three reactive functions of which two are hydroxyl groups. The two hydroxyl groups of the ranching chain extender is acetal protected by reaction between said two hydroxyl groups and an acetal-forming carbonyl compound, preferably an aldehyde. The acetal protected branching chain extender is then employed for addition to the initiator molecule of a first branching generation followed by an optional deprotection of the hydroxyl groups by decomposition of acetals and for addition in repeated steps of further branching generations.

Abstract: The present application is directed to a heterocyclic compound having the structural formula: ##STR1## where R is hydrogen, C.sub.1 -C.sub.2 alkyl, cyclohexyl, phenyl, benzyl, phenylethyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 4-(carboxylamine)butyl or diphenylmethyl; M is hydrogen, sodium, potassium, magnesium or ammonium; and x is 1 or 2. The heterocyclic compound having the aforementioned structural formula finds application in many pharmaceutical applications.

Abstract: The present invention relates to the use of an ester of inositoltrisphosphate for the preparation of a medicament for preventing, alleviating or combatting inflammatory conditions in mammals including man.Injury or destruction of tissues should be understood as damage to an aggregation of specialized cells with a particular function both internally and externally in the body, such as different organs or parts of these, vessels, skin etc.Tissue damage involves a complex series of events such as dilatation of vessel walls e.g. arterioles, capillaries and venules, increased permeability of fluids including e.g. plasma proteins and increased blood flow. Increased vascular leakage often results in extravasation and oedema formation which characterize the damage of different tissues.Often tissue damage and inflammatory conditions are characterized by signs of pain, heat, redness, swelling and loss of function.

Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises an aliphatic ester or ether for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one aliphatic ester or ether compound for the preparing of an inositol phosphate containing medicament with improved bioavailability of inositol phosphate in mammals including man at non-parenteral administration.